HERON THERAPEUTICS INC (HRTX)

Company Profile

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 203 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.

Company Info

HERON THERAPEUTICS INC

4242 Campus Point Court, Suite 200

San Diego CALIFORNIA 92121

P: 18582514400

CEO: Barry Quart

Employees: 203

Website: https://www.herontx.com/